Vice president, operations
Kelly Magnuson is the vice president of operations at Proclara. Prior to Proclara, she served as vice president of clinical operations at Kura Oncology where she designed the pivotal program operational strategy for tipifarnib, a farnesyl transferase, in HRAS positive squamous cell head and neck cancer. Prior to Kura, she served as vice president of program leadership at Aegerion Pharmaceuticals where she led the design and execution of the global commercial strategies for the rare disease products Juxtapid and Myalept. Prior to Aegerion, she was vice president, strategic Initiatives, operational excellence, and communications at Integra LifeSciences; vice president, strategic planning, and portfolio management for the Human Genetic Therapies Division at Shire Pharmaceuticals; and portfolio director for the Oncology Business Unit of Pfizer Pharmaceuticals. During her career, she has also created and delivered project management training and certification courses within the industry and in academia. Ms. Magnuson holds an MBA from Rensselaer Polytechnic Institute, a Master of Science Degree in Microbiology from the University of Illinois, a Bachelor of Science Degree in Science Education from the University of Minnesota and is a certified Project Management Professional.